Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey, 06100
- Novartis Investigative Site
-
Canakkale, Turkey
- Novartis Investigative Site
-
Fatih / Istanbul, Turkey, 34098
- Novartis Investigative Site
-
Kinikli / Denizli, Turkey, 20070
- Novartis Investigative Site
-
Kocaeli, Turkey, 41380
- Novartis Investigative Site
-
Malatya, Turkey, 44280
- Novartis Investigative Site
-
Mersin, Turkey, 33079
- Novartis Investigative Site
-
Talas / Kayseri, Turkey, 38039
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, above 18 years of age
- Diagnosis of essential hypertension
- Newly diagnosed,
- Previously untreated, or Currently untreated (not on regular antihypertensive treatment during the previous at least 1-month period)
- Written informed consent
Exclusion Criteria:
- Known or suspected secondary hypertension
- eGFR lower than 30 mL/min
- Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide)
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women
- Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: amlodipine/valsartan
All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled.
The duration of treatment period is 8 weeks.
|
Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
Time Frame: At week 4 and 8
|
Control rate of BP defined as BP lower than 140/90 mmHg at office visits
|
At week 4 and 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8
Time Frame: baseline, week 4, week 8
|
Change in systolic blood pressure measured in office from baseline at week 4 and 8.
|
baseline, week 4, week 8
|
|
Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8
Time Frame: baseline, week 4, week 8
|
Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.
|
baseline, week 4, week 8
|
|
Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
Time Frame: At week 4 and 8
|
Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (>100 mEq/day)
|
At week 4 and 8
|
|
SBP and DBP in Patients With High Sodium Intake at Week 4 and 8
Time Frame: At week 4 and 8
|
Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.
|
At week 4 and 8
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Essential Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Valsartan
- Amlodipine, Valsartan Drug Combination
Other Study ID Numbers
Other Study ID Numbers
- CVAA489ATR04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.